Stock Track | Pacific Biosciences Plunges 8.62% After Hours on Mixed Q3 Results and Revenue Decline

Stock Track11-06

Shares of Pacific Biosciences of California (PACB) plummeted 8.62% in after-hours trading on Wednesday following the release of the company's third-quarter 2025 financial results. The mixed report showed improvements in some areas but also highlighted ongoing challenges for the DNA sequencing technology company.

For the third quarter, PacBio reported revenue of $38.4 million, down from $40.0 million in the same quarter last year and slightly below analyst expectations of $40.21 million. However, the company's adjusted earnings per share came in at -$0.12, beating the analyst estimate of -$0.15. The GAAP net loss for the quarter was $38.0 million, or $0.13 per share.

Despite the revenue decline, PacBio showed improvements in other areas. The company's non-GAAP gross margin expanded to 42%, up from 33% in Q3 2024, reflecting better operational efficiency. Operating expenses were also reduced as part of the company's cost-cutting efforts. However, investors appear concerned about the declining cash position, which fell to $298.7 million from $471.1 million a year ago. This drop in cash reserves, coupled with the ongoing revenue challenges, likely contributed to the significant after-hours stock decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135385546?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 09:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135385546","market":"hk","top_or_hot":-1,"title":"Stock Track | Pacific Biosciences Plunges 8.62% After Hours on Mixed Q3 Results and Revenue Decline","media":"Stock Track","content":"<p>Shares of Pacific Biosciences of California (PACB) plummeted 8.62% in after-hours trading on Wednesday following the release of the company's third-quarter 2025 financial results. The mixed report showed improvements in some areas but also highlighted ongoing challenges for the DNA sequencing technology company.</p>\n\n<p>For the third quarter, PacBio reported revenue of $38.4 million, down from $40.0 million in the same quarter last year and slightly below analyst expectations of $40.21 million. However, the company's adjusted earnings per share came in at -$0.12, beating the analyst estimate of -$0.15. The GAAP net loss for the quarter was $38.0 million, or $0.13 per share.</p>\n\n<p>Despite the revenue decline, PacBio showed improvements in other areas. The company's non-GAAP gross margin expanded to 42%, up from 33% in Q3 2024, reflecting better operational efficiency. Operating expenses were also reduced as part of the company's cost-cutting efforts. However, investors appear concerned about the declining cash position, which fell to $298.7 million from $471.1 million a year ago. This drop in cash reserves, coupled with the ongoing revenue challenges, likely contributed to the significant after-hours stock decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pacific Biosciences Plunges 8.62% After Hours on Mixed Q3 Results and Revenue Decline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pacific Biosciences Plunges 8.62% After Hours on Mixed Q3 Results and Revenue Decline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-06 09:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Pacific Biosciences of California (PACB) plummeted 8.62% in after-hours trading on Wednesday following the release of the company's third-quarter 2025 financial results. The mixed report showed improvements in some areas but also highlighted ongoing challenges for the DNA sequencing technology company.</p>\n\n<p>For the third quarter, PacBio reported revenue of $38.4 million, down from $40.0 million in the same quarter last year and slightly below analyst expectations of $40.21 million. However, the company's adjusted earnings per share came in at -$0.12, beating the analyst estimate of -$0.15. The GAAP net loss for the quarter was $38.0 million, or $0.13 per share.</p>\n\n<p>Despite the revenue decline, PacBio showed improvements in other areas. The company's non-GAAP gross margin expanded to 42%, up from 33% in Q3 2024, reflecting better operational efficiency. Operating expenses were also reduced as part of the company's cost-cutting efforts. However, investors appear concerned about the declining cash position, which fell to $298.7 million from $471.1 million a year ago. This drop in cash reserves, coupled with the ongoing revenue challenges, likely contributed to the significant after-hours stock decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PACB","symbol_name":"Pacific Biosciences of Californi","start_time":0,"source_url":"","article_id":"1135385546","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135385546","pubTimestamp":1762391778,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Pacific Biosciences of California (PACB) plummeted 8.62% in after-hours trading on Wednesday following the release of the company's third-quarter 2025 financial results. The mixed report...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PACB":"Pacific Biosciences of Californi"},"translate_title":"个股追踪|太平洋生物科技盘后暴跌8.62%Q3业绩好坏参半营收下滑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PACB":1},"content_text":"Shares of Pacific Biosciences of California (PACB) plummeted 8.62% in after-hours trading on Wednesday following the release of the company's third-quarter 2025 financial results. The mixed report showed improvements in some areas but also highlighted ongoing challenges for the DNA sequencing technology company.\nFor the third quarter, PacBio reported revenue of $38.4 million, down from $40.0 million in the same quarter last year and slightly below analyst expectations of $40.21 million. However, the company's adjusted earnings per share came in at -$0.12, beating the analyst estimate of -$0.15. The GAAP net loss for the quarter was $38.0 million, or $0.13 per share.\nDespite the revenue decline, PacBio showed improvements in other areas. The company's non-GAAP gross margin expanded to 42%, up from 33% in Q3 2024, reflecting better operational efficiency. Operating expenses were also reduced as part of the company's cost-cutting efforts. However, investors appear concerned about the declining cash position, which fell to $298.7 million from $471.1 million a year ago. This drop in cash reserves, coupled with the ongoing revenue challenges, likely contributed to the significant after-hours stock decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135385546","isCrawlerRequest":true}